We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Nabs Accelerated Reviews for Elotuzumab in U.S. and EU
BMS Nabs Accelerated Reviews for Elotuzumab in U.S. and EU
The FDA has granted priority review for Bristol-Myers Squibb and AbbVie’s Empliciti for the treatment of multiple myeloma in patients who have received one or more previous therapies — giving it a PDUFA date of Feb. 29, 2016.